Showing results (221-230 of 238) with videos related to

Sort By:
Pageof 24
The Lancet. Oncology|June 5, 2018
Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort studyBo Jan Noordman, Manon C W Spaander, Roelf Valkema, et al.
Endoscopy International Open|August 27, 2025
Safety of surveillance endoscopy and EUS of the esophagus after neoadjuvant chemoradiotherapy: Results from the (pre)SANO trialSanjiv S G Gangaram Panday, Low Kuan Yean, Tanya M Bisseling, et al.
The British Journal of Surgery|July 7, 2023
Active surveillance of oesophageal cancer after response to neoadjuvant chemoradiotherapy: dysphagia is uncommonMaria J Valkema, Manon C W Spaander, Jurjen J Boonstra, et al.
BMC Medical Physics|August 2, 2008
NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial)Mark van Heijl, Jikke M T Omloo, Mark I van Berge Henegouwen, et al.
Annals of Surgical Oncology|July 27, 2024
Interval Metastases After Neoadjuvant Chemoradiotherapy for Patients with Locally Advanced Esophageal Cancer: A Multicenter Observational Cohort StudyCharlène J van der Zijden, Pieter C van der Sluis, Bianca Mostert, et al.
Annals of Surgery|May 25, 2026
Pathological Outcomes After Uncertain Response to Neoadjuvant Chemoradiotherapy in Esophageal CancerSanjiv S G Gangaram Panday, Dion In 't Veld, Bianca Mostert, et al.
BMC Cancer|February 8, 2018
Neoadjuvant chemoradiotherapy plus surgery versus active surveillance for oesophageal cancer: a stepped-wedge cluster randomised trialBo Jan Noordman, Bas P L Wijnhoven, Sjoerd M Lagarde, et al.
Annals of Surgery|October 9, 2019
Active Surveillance Versus Immediate Surgery in Clinically Complete Responders After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Propensity Matched StudyBerend J van der Wilk, Bo J Noordman, Lisanne K A Neijenhuis, et al.
Trials|May 18, 2021
Updated protocol of the SANO trial: a stepped-wedge cluster randomised trial comparing surgery with active surveillance after neoadjuvant chemoradiotherapy for oesophageal cancerBen M Eyck, Berend J van der Wilk, Bo Jan Noordman, et al.
The Lancet. Oncology|March 20, 2025
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trialBerend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, et al.
Pageof 24